Thorsten Waloschek/LinkedIn
Dec 21, 2025, 02:24
Thorsten Waloschek: New Study Highlights Preeclampsia Risk Stratification Benefits
Thorsten Waloschek, CEO of NeoPredics AG, shared a post on LinkedIn:
“This is an important signal for maternal health innovation in pregnancy.
A large new study shows that identifying women at higher risk of preeclampsia late in pregnancy, and acting on that risk with planned early-term birth, reduced term preeclampsia by around 30%.
Risk stratification, biomarkers, and structured decision-making during pregnancy can change outcomes – even without new drugs. This reinforces how much potential still sits in smarter diagnostics and data-driven pathways to protect mothers’ cardiovascular health during pregnancy.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Mar 21, 2026, 15:00Samantha Butts Shares Personal and Professional Insights in ASRM Close Up
-
Mar 21, 2026, 14:47Scammers Are Targeting ESHRE2026 Attendees – ESHRE
-
Mar 21, 2026, 14:26No Obvious Harm From Prolonged Oocyte Cryostorage – RBMO
-
Mar 21, 2026, 14:13Empowering Change: Health Systems at the Forefront of Ending FGM/C! – FIGO
-
Mar 21, 2026, 09:56Expanded Carrier Screening: Clinical, Ethical, and Psychosocial Perspectives from Ghent – ESHRE
-
Mar 21, 2026, 09:53Impact of Male Obesity on Embryo Development and Miscarriage Risk – Fertility and Sterility
-
Mar 20, 2026, 17:06Christopher Robinson: AJOG Expert Review on Placenta Accreta After Cesarean
-
Mar 20, 2026, 16:53HCG Failure and Trigger Strategies in IVF – Fertility Plus
-
Mar 20, 2026, 16:38Secure Your Early Bird Ticket for RCOG Annual Professional Development Conference – RCOG